- Home
- FMAO vs NPCE Comparison
FMAO vs NPCE Comparison
Compare FMAO & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- NPCE
- Stock Information
- Founded
- FMAO 1897
- NPCE 1997
- Country
- FMAO United States
- NPCE United States
- Employees
- FMAO N/A
- NPCE N/A
- Industry
- FMAO Savings Institutions
- NPCE Medical Specialities
- Sector
- FMAO Finance
- NPCE Health Care
- Exchange
- FMAO Nasdaq
- NPCE Nasdaq
- Market Cap
- FMAO 358.1M
- NPCE 363.2M
- IPO Year
- FMAO N/A
- NPCE 2021
- Fundamental
- Price
- FMAO $23.68
- NPCE $10.41
- Analyst Decision
- FMAO
- NPCE Strong Buy
- Analyst Count
- FMAO 0
- NPCE 6
- Target Price
- FMAO N/A
- NPCE $16.67
- AVG Volume (30 Days)
- FMAO 20.6K
- NPCE 128.0K
- Earning Date
- FMAO 10-28-2025
- NPCE 11-11-2025
- Dividend Yield
- FMAO 3.83%
- NPCE N/A
- EPS Growth
- FMAO 38.39
- NPCE N/A
- EPS
- FMAO 2.16
- NPCE N/A
- Revenue
- FMAO $108,632,000.00
- NPCE $88,570,000.00
- Revenue This Year
- FMAO $3.38
- NPCE $22.13
- Revenue Next Year
- FMAO $6.39
- NPCE $6.07
- P/E Ratio
- FMAO $10.71
- NPCE N/A
- Revenue Growth
- FMAO 13.86
- NPCE 23.32
- 52 Week Low
- FMAO $20.88
- NPCE $5.45
- 52 Week High
- FMAO $34.15
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- FMAO 41.51
- NPCE 50.88
- Support Level
- FMAO $22.89
- NPCE $10.15
- Resistance Level
- FMAO $25.06
- NPCE $11.19
- Average True Range (ATR)
- FMAO 0.92
- NPCE 0.52
- MACD
- FMAO -0.16
- NPCE -0.05
- Stochastic Oscillator
- FMAO 31.16
- NPCE 40.94
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.